Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7111388 | 1.00 | MEN1 (0.33) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL6120490 | 1.00 | MEN1 (0.33) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL6791247 | 1.00 | MEN1 (0.33) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL7111393 | 1.00 | MEN1 (0.33) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL27496485 | 1.00 | MEN1 (0.33) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL18826131 | 0.92 | MEN1 (0.34) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL11098782 | 0.87 | MEN1 (0.32) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL9841640 | 0.85 | MEN1 (0.38) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL9841180 | 0.85 | MEN1 (0.38) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL11361221 | 0.85 | MEN1 (0.38) | MEN1KMT2AKDM4CNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288430-B2 | Spiro(5.5)undecane derivatives | GRUNENTHAL GMBH (DE) | 2012-10-16 | — | — | US | disclosed |
| WO-2012067663-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-05-24 | — | — | WO | disclosed |
| EP-2257526-B1 | SPIRO(5.5)UNDECANE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2011-12-14 | — | — | EP | disclosed |
| CN-102083790-A | Spiro (5.5) undecane derivatives | GRUENENTHAL GMBH | 2011-06-01 | — | — | CN | disclosed |
| EP-2257526-A1 | SPIRO(5.5)UNDECANE DERIVATIVES | Grünenthal GmbH (DE) | 2010-12-08 | — | — | EP | disclosed |
| WO-2009118169-A1 | SPIRO(5.5)UNDECANE DERIVATIVES | Grünenthal GmbH (DE) | 2009-10-01 | — | — | WO | disclosed |
| US-20090247505-A1 | SPIRO(5.5)UNDECANE DERIVATIVES | GRUNENTHAL GMBH (DE) | 2009-10-01 | — | — | US | disclosed |
| US-6071932-A | SUPPRESSING ABSORPTION OF GAMMA-AMINOBUTYRIC ACID FOR TREATMENT OF NERVOUS SYSTEM DISORDERS | BRITISH TECHNOLOGY GROUP INTERCORPORATE LICENSING LIMITED (GB) | 2000-06-06 | — | — | US | disclosed |
| EP-0823905-A1 | NOVEL HETEROCYCLIC CHEMISTRY | NOVO NORDISK A/S (DK) | 1998-02-18 | — | — | EP | disclosed |
| WO-1996034863-A1 | NOVEL HETEROCYCLIC CHEMISTRY | NOVO NORDISK A/S (DK) | 1996-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247505-A1 | SPIRO(5.5)UNDECANE DERIVATIVES | OPRL1, OPRD1, OPRM1 | MEN1 4064/4885KMT2A 4255/4885KDM4C 4657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.